Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.71 |
| ▸ | RARB | P10826 | 3/20 | 0.67 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.61 |
| ▸ | THRA | P10827 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053280 | 1.00 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL5206359 | 1.00 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL2387345 | 1.00 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL2399489 | 1.00 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL1022325 | 1.00 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL8728342 | 1.00 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL9161795 | 1.00 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL10045771 | 1.00 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL4209056 | 1.00 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL1023839 | 0.98 | TP53 (0.70) | TP53TSHRPLA2G4BRARBPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0440329-A1 | S-substituted carbonyl substituted betathioacrylamide biocides and fungicides | ROHM AND HAAS COMPANY (US) | 1991-08-07 | — | — | EP | claimed |
| US-9700543-B2 | GLP-1 receptor stabilizers and modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-07-11 | — | — | US | disclosed |
| EP-2713722-B1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160310471-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC | 2016-10-27 | — | — | US | disclosed |
| US-9422231-B2 | Method for inhibiting Trypanosoma cruzi | HOWARD UNIVERSITY (US) | 2016-08-23 | — | — | US | disclosed |
| US-9278910-B2 | GLP-1 receptor stabilizers and modulators | RECEPTOS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150073177-A1 | METHOD FOR INHIBITING TRYPANOSOMA CRUZI | HOWARD UNIVERRSITY (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140336185-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC | 2014-11-13 | — | — | US | disclosed |
| US-20140336187-A1 | METHODS FOR TREATING LEISHMANIASIS | HOWARD UNIVERSITY | 2014-11-13 | — | — | US | disclosed |
| US-8816121-B2 | GLP-1 receptor stabilizers and modulators | RECEPTOS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-0248335-A2 | Chiral esters of alpha-substituted carboxylic acids and mesogeneous pyrimidine-5-yl-phenols, and their use as dopants in liquid-crystal phases | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-12-09 | — | — | EP | disclosed |
| EP-0218728-A1 | PHENYLENE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1987-04-22 | — | — | EP | disclosed |
| WO-1986005779-A1 | PHENYLENE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-10-09 | — | — | WO | disclosed |
| US-4481149-A | LIQUID CRYSTALS | DAIKIN KOGYO CO., LTD. (JP) | 1984-11-06 | — | — | US | disclosed |
| US-4393231-A | LIQUID CRYSTALS | DAIKIN KOGYO CO., LTD. (JP) | 1983-07-12 | — | — | US | disclosed |
| US-4308162-A | Novel yellow azo dyes and dichroic liquid crystal compositions made therewith | GENERAL ELECTRIC COMPANY (US) | 1981-12-29 | — | — | US | disclosed |
| US-4308161-A | FOR UPGRADING BLACK COLOR OF BLACK LIQUID CRYSTAL DISPLAYS | GENERAL ELECTRIC COMPANY (US) | 1981-12-29 | — | — | US | disclosed |
| US-4308164-A | Novel yellow azo dyes and dichroic liquid crystal composition made therewith | GENERAL ELECTRIC COMPANY (US) | 1981-12-29 | — | — | US | disclosed |
| US-4308163-A | IMPROVING BLACK COLOR OF DICHROIC DYES | GENERAL ELECTRIC COMPANY (US) | 1981-12-29 | — | — | US | disclosed |
| US-4029594-A | Novel liquid crystal compounds and electro-optic devices incorporating them | RCA CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336185-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | GLP1R, GIPR, GHSR | TP53 3447/4885TSHR 31/4885PLA2G4B 2051/4885 |
| US-20140336187-A1 | METHODS FOR TREATING LEISHMANIASIS | LSS, CYP51A1, NQO1 | TP53 3885/4885TSHR 3995/4885PLA2G4B 2124/4885 |
| US-20150073177-A1 | METHOD FOR INHIBITING TRYPANOSOMA CRUZI | PCNA, NQO1, NQO2 | TP53 3360/4885TSHR 2579/4885PLA2G4B 2643/4885 |
| US-20160310471-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | GLP1R, GIPR, GHSR | TP53 3447/4885TSHR 31/4885PLA2G4B 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.